Skip to main content

14.08.2019 | Original Article

Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes

verfasst von: Chia-Hsien Chang, Motonobu Sakaguchi

Erschienen in: Diabetology International

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To identify the association of type 2 diabetes (T2DM) and liver disease with elevated ALT and factors associated with increased ALT in patients with and without T2DM.

Design and setting

We performed a retrospective study in adults with ≥ 2 claims for blood tests recorded in the Medical Data Vision claims database between 2010 and 2016.

Participants

Patients were entered into T2DM and non-DM groups based on diagnosis and medication claim codes.

Primary outcome measure

The primary endpoint was the first follow-up ALT elevation over three times the normal value, and etiologies were categorized by subsequent diagnoses. We estimated the ALT elevation incidence and association with T2DM using Poisson regression and Cox proportional hazard models.

Results

We identified 3161 cases of elevated ALT in 104,903 patients (follow-up, 280,659 patient-years). The age- and sex-adjusted incidence of elevated ALT in the T2DM group (13.47 per 1000 patient-years; 95% confidence interval (CI) 12.53–14.48) was significantly higher than that in the non-DM group (8.43 per 1000 patient-years; 95% CI 7.72–9.20, p < 0.0001). Compared to the non-DM group, the T2DM group had an approximately 3.5 times higher risk of fatty liver-related ALT elevation (adjusted hazard ratio (HR), 3.54; 95% CI 1.90–6.58). T2DM was not associated with an increased incidence of jointly elevated ALT and total bilirubin (adjusted HR, 0.94; 95% CI 0.77–1.15).

Conclusion

T2DM is strongly associated with increased liver enzymes secondary to fatty liver. The causes of liver enzyme abnormalities were not fully characterized due to a high proportion of unexplained ALT elevation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Public Policy Committee of the American Association for the Study of Liver D. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.CrossRef Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Public Policy Committee of the American Association for the Study of Liver D. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.CrossRef
2.
Zurück zum Zitat Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005;71:1105–10.PubMed Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005;71:1105–10.PubMed
3.
Zurück zum Zitat Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.CrossRef Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.CrossRef
4.
Zurück zum Zitat Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95.CrossRef Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95.CrossRef
5.
Zurück zum Zitat Miyake Y, Eguchi H, Shinchi K, Oda T, Sasazuki S, Kono S. Glucose intolerance and serum aminotransferase activities in Japanese men. J Hepatol. 2003;38:18–23.CrossRef Miyake Y, Eguchi H, Shinchi K, Oda T, Sasazuki S, Kono S. Glucose intolerance and serum aminotransferase activities in Japanese men. J Hepatol. 2003;38:18–23.CrossRef
6.
Zurück zum Zitat Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring). 2007;15:1841–50.CrossRef Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring). 2007;15:1841–50.CrossRef
7.
Zurück zum Zitat Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, et al. Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism. 2009;58:1067–75.CrossRef Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, et al. Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism. 2009;58:1067–75.CrossRef
8.
Zurück zum Zitat Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-way relationship. J Diabetes Complicat. 2013;27:301–2.CrossRef Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-way relationship. J Diabetes Complicat. 2013;27:301–2.CrossRef
9.
Zurück zum Zitat Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–48.CrossRef Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–48.CrossRef
10.
Zurück zum Zitat Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, et al. Clinically significant chronic liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. QJM. 2016;109:249–56.CrossRef Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, et al. Clinically significant chronic liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. QJM. 2016;109:249–56.CrossRef
11.
Zurück zum Zitat Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–7.CrossRef Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–7.CrossRef
12.
Zurück zum Zitat Saeed MJ, Olsen MA, Powderly WG, Presti RM. Diabetes mellitus is associated with higher risk of developing decompensated cirrhosis in chronic hepatitis C patients. J Clin Gastroenterol. 2017;51:70–6.CrossRef Saeed MJ, Olsen MA, Powderly WG, Presti RM. Diabetes mellitus is associated with higher risk of developing decompensated cirrhosis in chronic hepatitis C patients. J Clin Gastroenterol. 2017;51:70–6.CrossRef
13.
Zurück zum Zitat Marcinak JF, Munsaka MS, Watkins PB, Ohira T, Smith N. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. 2018;41:625–40.CrossRef Marcinak JF, Munsaka MS, Watkins PB, Ohira T, Smith N. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. 2018;41:625–40.CrossRef
14.
Zurück zum Zitat Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–15.CrossRef Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–15.CrossRef
15.
Zurück zum Zitat Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633–40.CrossRef Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633–40.CrossRef
16.
Zurück zum Zitat Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRef Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRef
17.
Zurück zum Zitat Morling JR, Strachan MW, Hayes PC, Butcher I, Frier BM, Reynolds RM, et al. Prevalence of abnormal plasma liver enzymes in older people with type 2 diabetes. Diabet Med. 2012;29:488–91.CrossRef Morling JR, Strachan MW, Hayes PC, Butcher I, Frier BM, Reynolds RM, et al. Prevalence of abnormal plasma liver enzymes in older people with type 2 diabetes. Diabet Med. 2012;29:488–91.CrossRef
18.
Zurück zum Zitat Hashikata H, Harada KH, Kagimura T, Nakamura M, Koizumi A. Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med. 2011;16:313–9.CrossRef Hashikata H, Harada KH, Kagimura T, Nakamura M, Koizumi A. Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med. 2011;16:313–9.CrossRef
21.
Zurück zum Zitat Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRef Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRef
22.
Zurück zum Zitat Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1731–41.CrossRef Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1731–41.CrossRef
23.
Zurück zum Zitat Makar GA, Weiner MG, Kimmel SE, Bennett D, Burke A, Yang YX, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17:43–51.CrossRef Makar GA, Weiner MG, Kimmel SE, Bennett D, Burke A, Yang YX, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17:43–51.CrossRef
24.
Zurück zum Zitat Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–5.CrossRef Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–5.CrossRef
25.
Zurück zum Zitat Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRef Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRef
26.
Zurück zum Zitat Ulcickas Yood M, Bortolini M, Casso D, Beck JG, Oliveria SA, Wells KE, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24:427–34.CrossRef Ulcickas Yood M, Bortolini M, Casso D, Beck JG, Oliveria SA, Wells KE, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24:427–34.CrossRef
27.
Zurück zum Zitat Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997;146:565–71.CrossRef Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997;146:565–71.CrossRef
28.
Zurück zum Zitat Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109:588–90.CrossRef Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109:588–90.CrossRef
29.
Zurück zum Zitat Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160–6.CrossRef Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160–6.CrossRef
30.
Zurück zum Zitat Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679–88.CrossRef Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679–88.CrossRef
31.
Zurück zum Zitat Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–9.CrossRef Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–9.CrossRef
32.
Zurück zum Zitat Shafqet M, Sharzehi K. Diabetes and the pancreatobiliary diseases. Curr Treat Options Gastroenterol. 2017;15:508–19.CrossRef Shafqet M, Sharzehi K. Diabetes and the pancreatobiliary diseases. Curr Treat Options Gastroenterol. 2017;15:508–19.CrossRef
Metadaten
Titel
Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes
verfasst von
Chia-Hsien Chang
Motonobu Sakaguchi
Publikationsdatum
14.08.2019
Verlag
Springer Japan
Erschienen in
Diabetology International
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-019-00405-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.